Keros Therapeutics, Inc. Increase Decrease In Operating Lease Liability
Keros Therapeutics, Inc. (KROS) reported Increase Decrease In Operating Lease Liability of -$1.01 million for the 6-month period ending 2022-06-30, per its 10-Q filed 2022-08-04.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2022-08-04
- Keros Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2022-06-30 was -$606.00K.
- Keros Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2022-03-31 was -$402.00K.
- Keros Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2021-12-31 was -$994.00K.
- Keros Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2021-09-30 was $605.00K.
- Keros Therapeutics, Inc. increase decrease in operating lease liability for fiscal 2021 was -$597.00K.
- Keros Therapeutics, Inc. increase decrease in operating lease liability for fiscal 2020 was -$376.00K.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2022-06-30 | -$606.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$1.01M 10-Q · filed 2022-08-04 | -$2.00M derived: sum of 3 quarters · filed 2022-08-04 | -$1.40M derived: sum of 4 quarters · filed 2022-08-04 |
| 2022-03-31 | -$402.00K 10-Q · filed 2022-05-05 | -$1.40M derived: sum of 2 quarters · filed 2022-05-05 | -$791.00K derived: sum of 3 quarters · filed 2022-05-05 | -$897.00K derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-12-31 | -$994.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-09 | -$389.00K derived: sum of 2 quarters · filed 2022-03-09 | -$495.00K derived: sum of 3 quarters · filed 2022-08-04 | -$597.00K 10-K · filed 2022-03-09 |
| 2021-09-30 | $605.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $499.00K derived: sum of 2 quarters · filed 2022-08-04 | $397.00K 10-Q · filed 2021-11-04 | $298.00K derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-06-30 | -$106.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$208.00K 10-Q · filed 2022-08-04 | -$307.00K derived: sum of 3 quarters · filed 2022-08-04 | -$401.00K derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | -$102.00K 10-Q · filed 2022-05-05 | -$201.00K derived: sum of 2 quarters · filed 2022-05-05 | -$295.00K derived: sum of 3 quarters · filed 2022-05-05 | |
| 2020-12-31 | -$99.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-09 | -$193.00K derived: sum of 2 quarters · filed 2022-03-09 | -$376.00K 10-K · filed 2022-03-09 | |
| 2020-09-30 | -$94.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | -$277.00K 10-Q · filed 2021-11-04 | ||
| 2020-06-30 | -$183.00K 10-Q · filed 2021-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |